Cell Biotech Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	26,716	17,139	4,757	7,884	8,458	9,860
Short-Term Investments	67,885	75,923	74,450	56,515	37,671	18,675
Trading Asset Securities	-	-	8,247	5,933	19,239	29,299
Cash & Short-Term Investments	94,601	93,062	87,454	70,332	65,368	57,834
Cash Growth	5.95%	6.41%	24.34%	7.59%	13.03%	5.37%
Accounts Receivable	5,259	4,357	3,991	4,595	4,566	4,664
Other Receivables	1,204	736.95	682.88	943.86	583.11	268.43
Receivables	6,727	5,362	4,976	5,740	5,330	5,216
Inventory	5,176	4,616	4,203	4,122	4,102	3,589
Prepaid Expenses	169.36	459.01	287.27	691.85	500.5	292.5
Other Current Assets	319.21	214.29	228.19	1,044	354.58	587.81
Total Current Assets	106,993	103,712	97,148	81,929	75,655	67,519
Property, Plant & Equipment	33,960	30,460	30,463	32,937	33,638	34,057
Long-Term Investments	501.94	501.94	501.94	501.94	3,786	8,427
Other Intangible Assets	1,161	1,176	1,606	1,599	1,793	1,536
Long-Term Accounts Receivable	0	0	0	0	0	0
Long-Term Deferred Tax Assets	270.14	270.14	216.96	182.29	449.3	751.56
Other Long-Term Assets	407.22	452.94	461.66	491.37	517.21	585.15
Total Assets	143,293	136,572	130,398	117,641	115,839	112,877
Accounts Payable	1,149	458.36	680.27	578.39	1,370	1,224
Accrued Expenses	623.85	395.45	481.51	489.15	443.91	470.95
Current Portion of Leases	219.22	350.13	650.28	621.14	600.78	402.89
Current Income Taxes Payable	1,436	187.23	1,404	-	1,038	814.73
Current Unearned Revenue	27.34	33.27	27.57	27.03	30.9	50.44
Other Current Liabilities	6,730	3,436	2,619	3,106	3,905	2,802
Total Current Liabilities	10,186	4,861	5,863	4,821	7,389	5,766
Long-Term Leases	74.19	75.25	366.66	934.17	357.79	423.49
Other Long-Term Liabilities	-	0	-	-	-	0
Total Liabilities	10,260	4,936	6,229	5,755	7,747	6,189
Common Stock	4,700	4,700	4,700	4,700	4,700	4,700
Additional Paid-In Capital	4,260	12,760	12,760	12,760	12,760	12,760
Retained Earnings	147,055	137,309	130,264	118,217	114,993	109,894
Treasury Stock	-23,978	-23,978	-23,978	-23,978	-23,978	-20,258
Comprehensive Income & Other	996.46	845.33	422.69	186.4	-382.91	-408.42
Shareholders' Equity	133,033	131,637	124,168	111,885	108,092	106,687
Total Liabilities & Equity	143,293	136,572	130,398	117,641	115,839	112,877
Total Debt	293.41	425.38	1,017	1,555	958.57	826.38
Net Cash (Debt)	94,308	92,636	86,437	68,777	64,409	57,007
Net Cash Growth	6.64%	7.17%	25.68%	6.78%	12.98%	6.47%
Net Cash Per Share	13784.79	13535.60	12628.32	10049.37	9342.06	8061.43
Filing Date Shares Outstanding	6.84	6.84	6.84	6.84	6.84	7.07
Total Common Shares Outstanding	6.84	6.84	6.84	6.84	6.84	7.07
Working Capital	96,807	98,852	91,286	77,108	68,266	61,754
Book Value Per Share	19438.61	19234.14	18142.94	16348.17	15793.91	15086.68
Tangible Book Value	131,872	130,461	122,563	110,286	106,299	105,151
Tangible Book Value Per Share	19269.00	19062.36	17908.31	16114.53	15531.88	14869.49
Land	9,696	9,696	9,696	9,765	9,765	9,765
Buildings	26,525	22,296	19,675	19,537	13,349	13,854
Machinery	26,414	26,322	25,847	25,644	7,228	8,033
Construction In Progress	88.2	117.7	385.42	338.95	993.9	247.26